Clinical relevance of VKORC1 (G-1639A and C1173T) and CYP2C9*3 among patients on warfarin

What is known and Objectives: Testing for cytochrome P450-2C9 (CYP2C9) and vitamin K epoxide reductase complex subunit 1 (VKORC1) variant alleles is recommended by the FDA for dosing of warfarin. However, dose prediction models derived from data obtained in one population may not be applicable to an...

Full description

Bibliographic Details
Published in:Journal of Clinical Pharmacy and Therapeutics
Main Author: Teh L.K.; Langmia I.M.; Fazleen Haslinda M.H.; Ngow H.A.; Roziah M.J.; Harun R.; Zakaria Z.A.; Salleh M.Z.
Format: Article
Language:English
Published: 2012
Online Access:https://www.scopus.com/inward/record.uri?eid=2-s2.0-84857946108&doi=10.1111%2fj.1365-2710.2011.01262.x&partnerID=40&md5=c11f16571a9381ef4498e3894b730ba8
id 2-s2.0-84857946108
spelling 2-s2.0-84857946108
Teh L.K.; Langmia I.M.; Fazleen Haslinda M.H.; Ngow H.A.; Roziah M.J.; Harun R.; Zakaria Z.A.; Salleh M.Z.
Clinical relevance of VKORC1 (G-1639A and C1173T) and CYP2C9*3 among patients on warfarin
2012
Journal of Clinical Pharmacy and Therapeutics
37
2
10.1111/j.1365-2710.2011.01262.x
https://www.scopus.com/inward/record.uri?eid=2-s2.0-84857946108&doi=10.1111%2fj.1365-2710.2011.01262.x&partnerID=40&md5=c11f16571a9381ef4498e3894b730ba8
What is known and Objectives: Testing for cytochrome P450-2C9 (CYP2C9) and vitamin K epoxide reductase complex subunit 1 (VKORC1) variant alleles is recommended by the FDA for dosing of warfarin. However, dose prediction models derived from data obtained in one population may not be applicable to another. We therefore studied the impact of genetic polymorphisms of CYP2C9 and VKORC1 on warfarin dose requirement in Malaysia. Methods: Patients who were attending clinics at our hospital and prescribed warfarin with stabilized INR levels of 2-4 were selected. DNA was extracted from blood samples and subsequently genotyped for CYP2C9*1,*2,*3, VKORC1 (G-1639A) and VKORC1 C1173T. Linear regression modelling using age, CYP2C9 and VKORC1 genotypes, sex, weight and height was undertaken to define a warfarin dosing algorithm. An initial model was developed using data from one cohort of patients and validated using data from a second cohort. Results and Discussion: A model which included age and variants of CYP2C9 and VKORC1 account for about 37% of the variability in warfarin dose required to achieve INR of 2-4. Among the parameters evaluated, only VKORC1 (G-1639A) and (C1173T) alleles, and age correlated with warfarin dose at 6 month. The mean dose predicted using the algorithm derived from cohort 1 was lower than the actual dose for cohort 2 (3·30 mg, SD 0·84 vs. 3·45 mg, SD 1·42). There was no relationship between INR values and the dose taken by the patients. Race, sex, weight and height did not correlate with dose. What is new and Conclusion: This study identifies factors which affect warfarin dosing in the Malaysia population. However, our best model does not account sufficiently for the variability in dose requirements for it to be used in dose prediction for the individual patient. Other important influential factors affecting warfarin dose requirement remain to be identified. © 2011 Blackwell Publishing Ltd.

13652710
English
Article
All Open Access; Gold Open Access
author Teh L.K.; Langmia I.M.; Fazleen Haslinda M.H.; Ngow H.A.; Roziah M.J.; Harun R.; Zakaria Z.A.; Salleh M.Z.
spellingShingle Teh L.K.; Langmia I.M.; Fazleen Haslinda M.H.; Ngow H.A.; Roziah M.J.; Harun R.; Zakaria Z.A.; Salleh M.Z.
Clinical relevance of VKORC1 (G-1639A and C1173T) and CYP2C9*3 among patients on warfarin
author_facet Teh L.K.; Langmia I.M.; Fazleen Haslinda M.H.; Ngow H.A.; Roziah M.J.; Harun R.; Zakaria Z.A.; Salleh M.Z.
author_sort Teh L.K.; Langmia I.M.; Fazleen Haslinda M.H.; Ngow H.A.; Roziah M.J.; Harun R.; Zakaria Z.A.; Salleh M.Z.
title Clinical relevance of VKORC1 (G-1639A and C1173T) and CYP2C9*3 among patients on warfarin
title_short Clinical relevance of VKORC1 (G-1639A and C1173T) and CYP2C9*3 among patients on warfarin
title_full Clinical relevance of VKORC1 (G-1639A and C1173T) and CYP2C9*3 among patients on warfarin
title_fullStr Clinical relevance of VKORC1 (G-1639A and C1173T) and CYP2C9*3 among patients on warfarin
title_full_unstemmed Clinical relevance of VKORC1 (G-1639A and C1173T) and CYP2C9*3 among patients on warfarin
title_sort Clinical relevance of VKORC1 (G-1639A and C1173T) and CYP2C9*3 among patients on warfarin
publishDate 2012
container_title Journal of Clinical Pharmacy and Therapeutics
container_volume 37
container_issue 2
doi_str_mv 10.1111/j.1365-2710.2011.01262.x
url https://www.scopus.com/inward/record.uri?eid=2-s2.0-84857946108&doi=10.1111%2fj.1365-2710.2011.01262.x&partnerID=40&md5=c11f16571a9381ef4498e3894b730ba8
description What is known and Objectives: Testing for cytochrome P450-2C9 (CYP2C9) and vitamin K epoxide reductase complex subunit 1 (VKORC1) variant alleles is recommended by the FDA for dosing of warfarin. However, dose prediction models derived from data obtained in one population may not be applicable to another. We therefore studied the impact of genetic polymorphisms of CYP2C9 and VKORC1 on warfarin dose requirement in Malaysia. Methods: Patients who were attending clinics at our hospital and prescribed warfarin with stabilized INR levels of 2-4 were selected. DNA was extracted from blood samples and subsequently genotyped for CYP2C9*1,*2,*3, VKORC1 (G-1639A) and VKORC1 C1173T. Linear regression modelling using age, CYP2C9 and VKORC1 genotypes, sex, weight and height was undertaken to define a warfarin dosing algorithm. An initial model was developed using data from one cohort of patients and validated using data from a second cohort. Results and Discussion: A model which included age and variants of CYP2C9 and VKORC1 account for about 37% of the variability in warfarin dose required to achieve INR of 2-4. Among the parameters evaluated, only VKORC1 (G-1639A) and (C1173T) alleles, and age correlated with warfarin dose at 6 month. The mean dose predicted using the algorithm derived from cohort 1 was lower than the actual dose for cohort 2 (3·30 mg, SD 0·84 vs. 3·45 mg, SD 1·42). There was no relationship between INR values and the dose taken by the patients. Race, sex, weight and height did not correlate with dose. What is new and Conclusion: This study identifies factors which affect warfarin dosing in the Malaysia population. However, our best model does not account sufficiently for the variability in dose requirements for it to be used in dose prediction for the individual patient. Other important influential factors affecting warfarin dose requirement remain to be identified. © 2011 Blackwell Publishing Ltd.
publisher
issn 13652710
language English
format Article
accesstype All Open Access; Gold Open Access
record_format scopus
collection Scopus
_version_ 1809677913667141632